Magazine Article | September 1, 2016

Great Expectations For Personalized Medicine Outside Oncology

Source: Life Science Leader

By Peter Keeling, CEO, and Steve Vitale, managing director, Diaceutics Group

Oncology has always been the front runner in personalized medicine, so this is where targeted therapies and diagnostics have, for the most part, been focused. However, there is new activity outside this area where biomarker and targeted approaches are proving successful.

There are now biomarker-driven therapies for diabetes and inflammatory diseases and neurological diseases. The number of targeted drugs in this space has doubled in five years, and while oncology still dominates as the single most important therapy area, development in other disease areas has increased exponentially.